NSF International buys up CRO Amarex

Microbiology lab
Amarex will continue to work from its U.S. office near Washington, D.C., while also building on its operations in Taiwan and its growing presence in Europe. (Pixabay/Sansiona)

Health organization NSF International is delving deeper into life sciences after buying up the majority stake of CRO Amarex Clinical Research.

Now to be integrated into NSF, Amarex will gain access to both its network and international scope, the group said.

Amarex will continue to operate from its U.S. office near Washington, D.C., while also building on its operations in Taiwan and its growing presence in Europe.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

NSF International has been around for 75 years, with a goal of “protecting and improving human health” by working on standards development, and it tests and certifies products for the food, water, health sciences and consumer goods sectors.

This deal links it to a deeper life sciences stage of its long history, building Amarex, itself 21 years old, into its organization. The CRO works with biotech and medtech companies on clinical trial work with a focus on oncology, central nervous system, wound healing, infectious disease, cardiovascular and urology.

“NSF International plays an important role in the pharmaceutical and biotech industry as a champion of quality, scientific rigor and best practices aimed at protecting and improving human health. Together with Amarex, we are creating a single source for integrated, expert health science consulting services across the entire product lifecycle,” said NSF International President and CEO Kevan Lawlor.

“Amarex is excited to join the NSF International family. Amarex will be able to leverage NSF International’s global infrastructure to expand our contract research capabilities and better serve clients with the design and execution of clinical trials and navigating the FDA, TFDA and EMA regulatory approval process,” said Amarex founder Kazem Kazempour, Ph.D., who will continue as president and CEO of Amarex.

“NSF International’s operational excellence will accelerate our expert team’s leap forward in the CRO market, and better help pharmaceutical, biotech and medical device/diagnostic companies develop products and services that will protect and improve human health while minimizing inefficiencies to save time and reduce unnecessary costs.”

Suggested Articles

Genesis Drug Discovery & Development has bought up New England Discovery Partners as it looks to boost its synthetic and medicinal chemistry.

Sanofi plans to incorporate its real-world data platform with Aetion’s analytics system to better develop studies for regulatory decision-making.

Major CRO player Pharmaceutical Product Development is set to go back on the public markets after announcing its IPO plans.